Julie Elizabeth Gibbs

Julie Elizabeth Gibbs

Auto-generated profile, based on publicly available information

Julie Elizabeth Gibbs

Centre for Biological Timing, University of Manchester, Manchester, UK.

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JGJulie E. Gibbs
Julie E. Gibbs
JBJohn F Blaikley
John F Blaikley
SBStephen Beesley
Stephen Beesley
LMLaura Matthews
Laura Matthews
KSKaren D. Simpson
Karen D. Simpson
ALAndrew S. I. Loudon
Andrew S. I. Loudon
Diurnal variation in inflammatory and immune function is evident in the physiology and pathology of humans and animals, but molecular mechanisms and mediating cell types that provide this gating remain unknown. By screening cytokine responses in mice to endotoxin challenge at different times of day, we reveal that the magnitude of response exhibited pronounced temporal dependence, yet only within a subset of proinflammatory cytokines. Disruption of the circadian clockwork in macrophages (primary effector cells of the innate immune system) by conditional targeting of a key clock gene ( bmal1 ) removed all temporal gating of endotoxin-induced cytokine response in cultured cells and in vivo. Loss of circadian gating was coincident with suppressed rev-erb α expression, implicating this nuclear receptor as a potential link between the clock and inflammatory pathways. This finding was confirmed in vivo and in vitro through genetic and pharmacological modulation of REV-ERB α activity. Circadian gating of endotoxin response was lost in rev-erb α −/− mice and in cultured macrophages from these animals, despite maintenance of circadian rhythmicity within these cells. Using human macrophages, which show circadian clock gene oscillations and rhythmic endotoxin responses, we demonstrate that administration of a synthetic REV-ERB ligand, or genetic knockdown of rev-erb α expression, is effective at modulating the production and release of the proinflammatory cytokine IL-6. This work demonstrates that the macrophage clockwork provides temporal gating of systemic responses to endotoxin, and identifies REV-ERBα as the key link between the clock and immune function. REV-ERBα may therefore represent a unique therapeutic target in human inflammatory disease.

16 April 2018 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
CSChristoph Scheiermann
Christoph Scheiermann
JGJulie Gibbs
Julie Gibbs
LILouise Ince
Louise Ince
ALAndrew Loudon
Andrew Loudon

27 July 2014 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JGJulie Gibbs
Julie Gibbs
LILouise Ince
Louise Ince
LMLaura Matthews
Laura Matthews
JMJunjie Mei
Junjie Mei
TBThomas Bell
Thomas Bell
ALAndrew Loudon
Andrew Loudon

15 March 2014 in Genes & Development
Verified
Journal Article
Open access
PDF file
VPVanja Pekovic-Vaughan
Vanja Pekovic-Vaughan
JGJulie Gibbs
Julie Gibbs
HYHikari Yoshitane
Hikari Yoshitane
NYNan Yang
Nan Yang
DPDharshika Pathiranage
Dharshika Pathiranage
QMQing-Jun Meng
Qing-Jun Meng
The disruption of the NRF2 (nuclear factor erythroid-derived 2-like 2)/glutathione-mediated antioxidant defense pathway is a critical step in the pathogenesis of several chronic pulmonary diseases and cancer. While the mechanism of NRF2 activation upon oxidative stress has been widely investigated, little is known about the endogenous signals that regulate the NRF2 pathway in lung physiology and pathology. Here we show that an E-box-mediated circadian rhythm of NRF2 protein is essential in regulating the rhythmic expression of antioxidant genes involved in glutathione redox homeostasis in the mouse lung. Using an in vivo bleomycin-induced lung fibrosis model, we reveal a clock “gated” pulmonary response to oxidative injury, with a more severe fibrotic effect when bleomycin was applied at a circadian nadir in NRF2 levels. Timed administration of sulforaphane, an NRF2 activator, significantly blocked this phenotype. Moreover, in the lungs of the arrhythmic ClockΔ19 mice, the levels of NRF2 and the reduced glutathione are constitutively low, associated with increased protein oxidative damage and a spontaneous fibrotic-like pulmonary phenotype. Our findings reveal a pivotal role for the circadian control of the NRF2/glutathione pathway in combating oxidative/fibrotic lung damage, which might prompt new chronotherapeutic strategies for the treatment of human lung diseases, including idiopathic pulmonary fibrosis.

9 August 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
QMQing-Jun Meng
Qing-Jun Meng
EMElizabeth S. Maywood
Elizabeth S. Maywood
DBDavid A. Bechtold
David A. Bechtold
WLWei-Qun Lu
Wei-Qun Lu
JLJian Li
Jian Li
ALAndrew S. I. Loudon
Andrew S. I. Loudon
Circadian pacemaking requires the orderly synthesis, posttranslational modification, and degradation of clock proteins. In mammals, mutations in casein kinase 1 (CK1) ε or δ can alter the circadian period, but the particular functions of the WT isoforms within the pacemaker remain unclear. We selectively targeted WT CK1ε and CK1δ using pharmacological inhibitors (PF-4800567 and PF-670462, respectively) alongside genetic knockout and knockdown to reveal that CK1 activity is essential to molecular pacemaking. Moreover, CK1δ is the principal regulator of the clock period: pharmacological inhibition of CK1δ, but not CK1ε, significantly lengthened circadian rhythms in locomotor activity in vivo and molecular oscillations in the suprachiasmatic nucleus (SCN) and peripheral tissue slices in vitro. Period lengthening mediated by CK1δ inhibition was accompanied by nuclear retention of PER2 protein both in vitro and in vivo. Furthermore, phase mapping of the molecular clockwork in vitro showed that PF-670462 treatment lengthened the period in a phase-specific manner, selectively extending the duration of PER2-mediated transcriptional feedback. These findings suggested that CK1δ inhibition might be effective in increasing the amplitude and synchronization of disrupted circadian oscillators. This was tested using arrhythmic SCN slices derived from Vipr2 −/− mice, in which PF-670462 treatment transiently restored robust circadian rhythms of PER2::Luc bioluminescence. Moreover, in mice rendered behaviorally arrhythmic by the Vipr2 −/− mutation or by constant light, daily treatment with PF-670462 elicited robust 24-h activity cycles that persisted throughout treatment. Accordingly, selective pharmacological targeting of the endogenous circadian regulator CK1δ offers an avenue for therapeutic modulation of perturbed circadian behavior.

30 April 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MPMarie Pariollaud
Marie Pariollaud
JGJulie E. Gibbs
Julie E. Gibbs
THThomas W. Hopwood
Thomas W. Hopwood
SBSheila Brown
Sheila Brown
NBNicola Begley
Nicola Begley
DRDavid Ray
David Ray
Recent studies reveal that airway epithelial cells are critical pulmonary circadian pacemaker cells, mediating rhythmic inflammatory responses. Using mouse models, we now identify the rhythmic circadian repressor REV-ERBα as essential to the mechanism coupling the pulmonary clock to innate immunity, involving both myeloid and bronchial epithelial cells in temporal gating and determining amplitude of response to inhaled endotoxin. Dual mutation of REV-ERBα and its paralog REV-ERBβ in bronchial epithelia further augmented inflammatory responses and chemokine activation, but also initiated a basal inflammatory state, revealing a critical homeostatic role for REV-ERB proteins in the suppression of the endogenous proinflammatory mechanism in unchallenged cells. However, REV-ERBα plays the dominant role, as deletion of REV-ERBβ alone had no impact on inflammatory responses. In turn, inflammatory challenges cause striking changes in stability and degradation of REV-ERBα protein, driven by SUMOylation and ubiquitination. We developed a novel selective oxazole-based inverse agonist of REV-ERB, which protects REV-ERBα protein from degradation, and used this to reveal how proinflammatory cytokines trigger rapid degradation of REV-ERBα in the elaboration of an inflammatory response. Thus, dynamic changes in stability of REV-ERBα protein couple the core clock to innate immunity.